Article Versions Notes

Tegeler CM, Scheid J, Rammensee H-G, Salih HR, Walz JS, Heitmann JS, Nelde A. HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. Cancers. 2022; 14(9):2260. https://doi.org/10.3390/cancers14092260

Tegeler, Christian M., Jonas Scheid, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz, Jonas S. Heitmann, and Annika Nelde. 2022. "HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients" Cancers 14, no. 9: 2260. https://doi.org/10.3390/cancers14092260

Tegeler, C. M., Scheid, J., Rammensee, H.-G., Salih, H. R., Walz, J. S., Heitmann, J. S., & Nelde, A. (2022). HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. Cancers, 14(9), 2260. https://doi.org/10.3390/cancers14092260